Guilin Sanjin Pharmaceutical released the interim report for 2024, with revenue of 1.068 billion yuan during the reporting period, a year-on-year decrease of 10.53%; net income attributable to shareholders of the listed company was 0.301 billion yuan, a year-on-year decrease of 20.70%.
桂林三金：上半年净利润3.01亿元 同比下降20.70%
Guilin Sanjin Pharmaceutical: the net income in the first half of the year was 0.301 billion yuan, a year-on-year decrease of 20.70%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.